Key result
Combinations of lipid-modifying therapy are likely needed for patients with type 2 diabetes and metabolic syndrome to achieve guideline targets and prevent cardiovascular disease.
Patients with type 2 diabetes and metabolic syndrome often require combination lipid-modifying therapy to achieve guideline-directed targets and prevent cardiovascular disease.
Supports combination lipid therapy in type 2 diabetes with metabolic syndrome; leaves open prospective outcome trials before practice change.
Type 2 diabetes mellitus and the closely related metabolic syndrome are associated with significant risk for cardiovascular disease. Recent evidence suggests that both conditions are increasing in epidemic proportions. Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism. All these lipoprotein disturbances accelerate atherosclerosis in these patients. It is likely that many patients will need combinations of lipid-modifying therapy to achieve American Diabetes Association (ADA), Adult Treatment Panel III, and American Heart Association (AHA)/American College of Cardiology (ACC) guidelines to help prevent cardiovascular disease and death.
No takes yet. Share an insight, caveat, or question.
Cottrell et al. (2003) conducted a review in Type 2 diabetes mellitus and metabolic syndrome. Lipid-modifying therapy was evaluated. Combinations of lipid-modifying therapy are likely needed for patients with type 2 diabetes and metabolic syndrome to achieve guideline targets and prevent cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: